Skip to main content
Top
Published in: European Journal of Nutrition 1/2014

01-02-2014 | Original Contribution

Lactobacillus GG-fermented milk prevents DSS-induced colitis and regulates intestinal epithelial homeostasis through activation of epidermal growth factor receptor

Authors: Kazutoyo Yoda, Kenji Miyazawa, Masataka Hosoda, Masaru Hiramatsu, Fang Yan, Fang He

Published in: European Journal of Nutrition | Issue 1/2014

Login to get access

Abstract

Background

Fermented milk is considered one of the best sources for efficient consumption of probiotic strains by hosts to promote good health. The purpose of this study was to investigate the effects of orally administering LGG-fermented milk (LGG milk) on intestinal inflammation and injury and to study the mechanisms of LGG milk’s action.

Methods

LGG milk and non-LGG-fermented milk (non-LGG milk) were administered through gavage to mice before and during dextran sodium sulfate (DSS)-induced intestinal injury and colitis. Inflammatory/injury score and colon length were assessed. Intestinal epithelial cells were treated with the soluble fraction of LGG milk to detect its effects on the epidermal growth factor receptor (EGFR) and its downstream target, Akt activation, cytokine-induced apoptosis, and hydrogen peroxide (H2O2)-induced disruption of tight junctions.

Results

LGG milk treatment significantly reduced DSS-induced colonic inflammation and injury, and colon shortening in mice, compared to that in non-LGG milk-treated and -untreated mice. The soluble fraction of LGG milk, but not non-LGG milk, stimulated the activation of EGFR and Akt in a concentration-dependent manner, suppressed cytokine-induced apoptosis, and attenuated H2O2-induced disruption of tight junction complex in the intestinal epithelial cells. These effects of LGG milk were blocked by the EGFR kinase inhibitor. LGG milk, but not non-LGG milk, contained two soluble proteins, p40 and p75, that have been reported to promote survival and growth of intestinal epithelial cells through the activation of EGFR. Depletion of p40 and p75 from LGG milk abolished the effects of LGG milk on prevention of cytokine-induced apoptosis and H2O2-induced disruption of tight junctions.

Conclusions

These results suggest that LGG milk may regulate intestinal epithelial homeostasis and potentially prevent intestinal inflammatory diseases through activation of EGFR by LGG-derived proteins.
Literature
1.
go back to reference Gilliland SE, Morelli L, Reid G (2001) Report of a joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food: health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria report. Córdoba, Argentina Gilliland SE, Morelli L, Reid G (2001) Report of a joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food: health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria report. Córdoba, Argentina
2.
go back to reference Szajewska H, Mrukowicz JZ (2001) Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr 33(Suppl 2):S17–S25CrossRef Szajewska H, Mrukowicz JZ (2001) Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr 33(Suppl 2):S17–S25CrossRef
3.
go back to reference Kawase M, He F, Kubota A, Harata G, Hiramatsu M (2010) Oral administration of lactobacilli from human intestinal tract protects mice against influenza virus infection. Lett Appl Microbiol 51:6–10 Kawase M, He F, Kubota A, Harata G, Hiramatsu M (2010) Oral administration of lactobacilli from human intestinal tract protects mice against influenza virus infection. Lett Appl Microbiol 51:6–10
4.
go back to reference Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E (2001) Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 357:1076–1079CrossRef Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E (2001) Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 357:1076–1079CrossRef
5.
go back to reference Kawase M, He F, Kubota A, Hiramatsu M, Saito H, Ishii T et al (2009) Effect of fermented milk prepared with two probiotic strains on Japanese cedar pollinosis in a double-blind placebo-controlled clinical study. Int J Food Microbiol 128:429–434CrossRef Kawase M, He F, Kubota A, Hiramatsu M, Saito H, Ishii T et al (2009) Effect of fermented milk prepared with two probiotic strains on Japanese cedar pollinosis in a double-blind placebo-controlled clinical study. Int J Food Microbiol 128:429–434CrossRef
6.
go back to reference Kawase M, He F, Kubota A, Harata G, Hiramatsu M (2009) Clinical effects of cell preparation of Lactobacillus GG and L. gasseri TMC0356 on perennial allergic rhinitis: a double-blind placebo-controlled trial. Int J Probio Prebio 4:241–248 Kawase M, He F, Kubota A, Harata G, Hiramatsu M (2009) Clinical effects of cell preparation of Lactobacillus GG and L. gasseri TMC0356 on perennial allergic rhinitis: a double-blind placebo-controlled trial. Int J Probio Prebio 4:241–248
7.
go back to reference Schultz M (2008) Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis 2008(14):1012–1018CrossRef Schultz M (2008) Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis 2008(14):1012–1018CrossRef
8.
go back to reference Fedorak RN, Madsen KL (2004) Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis 10:286–299CrossRef Fedorak RN, Madsen KL (2004) Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis 10:286–299CrossRef
9.
go back to reference Saxelin M (2008) Probiotic formulations and applications, the current probiotics market, and changes in the marketplace: a European perspective. Clin Infect Dis 46(Suppl 2):S76–S79; discussion S144–S51 Saxelin M (2008) Probiotic formulations and applications, the current probiotics market, and changes in the marketplace: a European perspective. Clin Infect Dis 46(Suppl 2):S76–S79; discussion S144–S51
10.
go back to reference Blayney D, Gehlhar M, Hilda CH, Jones K, Langley S, Normile HA, et al (2006) Appendix A. In: World production and trade by country and product USDA economic research report number 28. USDA, Washington pp 30–44 Blayney D, Gehlhar M, Hilda CH, Jones K, Langley S, Normile HA, et al (2006) Appendix A. In: World production and trade by country and product USDA economic research report number 28. USDA, Washington pp 30–44
11.
go back to reference Hu D (2009) China: dairy product quality as the new industry driver. In: Animal Production and Health Commission for Asia and The Pacific. FAO Regional Office for Asia and The Pacific, Bangkok, pp 22–43 Hu D (2009) China: dairy product quality as the new industry driver. In: Animal Production and Health Commission for Asia and The Pacific. FAO Regional Office for Asia and The Pacific, Bangkok, pp 22–43
12.
13.
go back to reference Yan F, Polk DB (2006) Probiotics as functional food in the treatment of diarrhea. Curr Opin Clin Nutr Metab Care 9:717–721CrossRef Yan F, Polk DB (2006) Probiotics as functional food in the treatment of diarrhea. Curr Opin Clin Nutr Metab Care 9:717–721CrossRef
14.
go back to reference Goldin BR, Gorbach SL (2008) Clinical indications for probiotics: an overview. Clin Infect Dis 46(Suppl 2):S96–100; discussion S144–S151 Goldin BR, Gorbach SL (2008) Clinical indications for probiotics: an overview. Clin Infect Dis 46(Suppl 2):S96–100; discussion S144–S151
15.
go back to reference Yan F, Polk DB (2002) Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem 277:50959–50965CrossRef Yan F, Polk DB (2002) Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem 277:50959–50965CrossRef
16.
go back to reference Yan F, Cao H, Cover TL, Whitehead R, Washington MK, Polk DB (2007) Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 132:562–575CrossRef Yan F, Cao H, Cover TL, Whitehead R, Washington MK, Polk DB (2007) Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 132:562–575CrossRef
17.
go back to reference Seth A, Yan F, Polk DB, Rao RK (2008) Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism. Am J Physiol Gastrointest Liver Physiol 294:G1060–G1069CrossRef Seth A, Yan F, Polk DB, Rao RK (2008) Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism. Am J Physiol Gastrointest Liver Physiol 294:G1060–G1069CrossRef
18.
go back to reference Yan F, Cao H, Cover TL, Washington MK, Shi Y, Liu L et al (2011) Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. J Clin Invest 121:2242–2253CrossRef Yan F, Cao H, Cover TL, Washington MK, Shi Y, Liu L et al (2011) Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. J Clin Invest 121:2242–2253CrossRef
19.
go back to reference Dieleman LA, Palmen MJ, Akol H, Bloemena E, Pena AS, Meuwissen SG et al (1998) Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 114:385–391CrossRef Dieleman LA, Palmen MJ, Akol H, Bloemena E, Pena AS, Meuwissen SG et al (1998) Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 114:385–391CrossRef
20.
go back to reference Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98:694–702 Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98:694–702
21.
go back to reference Bauerl C, Perez-Martinez G, Yan F, Polk DB, Monedero V (2010) Functional analysis of the p40 and p75 proteins from Lactobacillus casei BL23. J Mol Microbiol Biotechnol 19:231–241CrossRef Bauerl C, Perez-Martinez G, Yan F, Polk DB, Monedero V (2010) Functional analysis of the p40 and p75 proteins from Lactobacillus casei BL23. J Mol Microbiol Biotechnol 19:231–241CrossRef
22.
go back to reference Shibolet O, Karmeli F, Eliakim R, Swennen E, Brigidi P, Gionchetti P et al (2002) Variable response to probiotics in two models of experimental colitis in rats. Inflamm Bowel Dis 8:399–406CrossRef Shibolet O, Karmeli F, Eliakim R, Swennen E, Brigidi P, Gionchetti P et al (2002) Variable response to probiotics in two models of experimental colitis in rats. Inflamm Bowel Dis 8:399–406CrossRef
23.
go back to reference Mileti E, Matteoli G, Iliev ID, Rescigno M (2009) Comparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex culture systems: prediction for in vivo efficacy. PLoS One 4:e7056CrossRef Mileti E, Matteoli G, Iliev ID, Rescigno M (2009) Comparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex culture systems: prediction for in vivo efficacy. PLoS One 4:e7056CrossRef
24.
go back to reference Lin PW, Myers LE, Ray L, Song SC, Nasr TR, Berardinelli AJ et al (2009) Lactobacillus rhamnosus blocks inflammatory signaling in vivo via reactive oxygen species generation. Free Radic Biol Med 47:1205–1211CrossRef Lin PW, Myers LE, Ray L, Song SC, Nasr TR, Berardinelli AJ et al (2009) Lactobacillus rhamnosus blocks inflammatory signaling in vivo via reactive oxygen species generation. Free Radic Biol Med 47:1205–1211CrossRef
25.
go back to reference Claes IJ, Lebeer S, Shen C, Verhoeven TL, Dilissen E, De Hertogh G et al (2010) Impact of lipoteichoic acid modification on the performance of the probiotic Lactobacillus rhamnosus GG in experimental colitis. Clin Exp Immunol 162:306–314CrossRef Claes IJ, Lebeer S, Shen C, Verhoeven TL, Dilissen E, De Hertogh G et al (2010) Impact of lipoteichoic acid modification on the performance of the probiotic Lactobacillus rhamnosus GG in experimental colitis. Clin Exp Immunol 162:306–314CrossRef
26.
go back to reference Jiang H, Przybyszewski J, Mitra D, Becker C, Brehm-Stecher B, Tentinger A et al (2011) Soy protein diet, but not Lactobacillus rhamnosus GG, decreases mucin-1, trefoil factor-3, and tumor necrosis factor-alpha in colon of dextran sodium sulfate-treated C57BL/6 mice. J Nutr 141:1239–1246CrossRef Jiang H, Przybyszewski J, Mitra D, Becker C, Brehm-Stecher B, Tentinger A et al (2011) Soy protein diet, but not Lactobacillus rhamnosus GG, decreases mucin-1, trefoil factor-3, and tumor necrosis factor-alpha in colon of dextran sodium sulfate-treated C57BL/6 mice. J Nutr 141:1239–1246CrossRef
27.
go back to reference Saxelin M, Elo S, Salminen S, Vapaatalo H (1991) Dose response colonisation of faeces after oral administration of Lactobacillus casei strain GG. Microb Ecol Health Dis 4:209–214CrossRef Saxelin M, Elo S, Salminen S, Vapaatalo H (1991) Dose response colonisation of faeces after oral administration of Lactobacillus casei strain GG. Microb Ecol Health Dis 4:209–214CrossRef
28.
go back to reference Saxelin M, Ahokas M, Salminen S (1993) Dose response on the faecal colonisation of Lactobacillus strain GG administered in two different formulations. Microb Ecol Health Dis 6:119–122CrossRef Saxelin M, Ahokas M, Salminen S (1993) Dose response on the faecal colonisation of Lactobacillus strain GG administered in two different formulations. Microb Ecol Health Dis 6:119–122CrossRef
29.
go back to reference Segawa S, Fujiya M, Konishi H, Ueno N, Kobayashi N, Shigyo T et al (2011) Probiotic-derived polyphosphate enhances the epithelial barrier function and maintains intestinal homeostasis through integrin-p38 MAPK pathway. PLoS One 6:e23278CrossRef Segawa S, Fujiya M, Konishi H, Ueno N, Kobayashi N, Shigyo T et al (2011) Probiotic-derived polyphosphate enhances the epithelial barrier function and maintains intestinal homeostasis through integrin-p38 MAPK pathway. PLoS One 6:e23278CrossRef
30.
go back to reference Tao Y, Drabik KA, Waypa TS, Musch MW, Alverdy JC, Schneewind O et al (2006) Soluble factors from Lactobacillus GG activate MAPKs and induce cytoprotective heat shock proteins in intestinal epithelial cells. Am J Physiol Cell Physiol 290:C1018–C1030CrossRef Tao Y, Drabik KA, Waypa TS, Musch MW, Alverdy JC, Schneewind O et al (2006) Soluble factors from Lactobacillus GG activate MAPKs and induce cytoprotective heat shock proteins in intestinal epithelial cells. Am J Physiol Cell Physiol 290:C1018–C1030CrossRef
Metadata
Title
Lactobacillus GG-fermented milk prevents DSS-induced colitis and regulates intestinal epithelial homeostasis through activation of epidermal growth factor receptor
Authors
Kazutoyo Yoda
Kenji Miyazawa
Masataka Hosoda
Masaru Hiramatsu
Fang Yan
Fang He
Publication date
01-02-2014
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nutrition / Issue 1/2014
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI
https://doi.org/10.1007/s00394-013-0506-x

Other articles of this Issue 1/2014

European Journal of Nutrition 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine